×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
IMAB – i-mab - american depositary shares (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
IMAB
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
4/6
08:34 pm
imab
ABL Bio Announces Grabody-B Brain Delivery Platform License Agreement with GSK to Develop Novel Medicines for Neurodegenerative Diseases [Yahoo! Finance]
High
Report
ABL Bio Announces Grabody-B Brain Delivery Platform License Agreement with GSK to Develop Novel Medicines for Neurodegenerative Diseases [Yahoo! Finance]
4/6
08:34 pm
imab
ABL Bio Announces Grabody-B Brain Delivery Platform License Agreement with GSK to Develop Novel Medicines for Neurodegenerative Diseases
High
Report
ABL Bio Announces Grabody-B Brain Delivery Platform License Agreement with GSK to Develop Novel Medicines for Neurodegenerative Diseases
4/6
08:15 pm
imab
ABL Bio Announces Grabody-B Brain Delivery Platform License Agreement with GSK to Develop Novel Medicines for Neurodegenerative Diseases
High
Report
ABL Bio Announces Grabody-B Brain Delivery Platform License Agreement with GSK to Develop Novel Medicines for Neurodegenerative Diseases
4/6
08:03 pm
imab
ABL Bio Announces Grabody-B Brain Delivery Platform License Agreement with GSK to Develop Novel Medicines for Neurodegenerative Diseases
High
Report
ABL Bio Announces Grabody-B Brain Delivery Platform License Agreement with GSK to Develop Novel Medicines for Neurodegenerative Diseases
4/4
08:14 am
imab
I-Mab (NASDAQ: IMAB) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $4.00 price target on the stock.
Medium
Report
I-Mab (NASDAQ: IMAB) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $4.00 price target on the stock.
4/4
08:14 am
imab
I-Mab (NASDAQ: IMAB) had its price target lowered by analysts at HC Wainwright from $8.00 to $7.00. They now have a "buy" rating on the stock.
Medium
Report
I-Mab (NASDAQ: IMAB) had its price target lowered by analysts at HC Wainwright from $8.00 to $7.00. They now have a "buy" rating on the stock.
4/3
04:01 pm
imab
I-Mab Reports Full Year 2024 Financial Results and Provides Business Update
Medium
Report
I-Mab Reports Full Year 2024 Financial Results and Provides Business Update
3/26
07:00 am
imab
I-Mab to Present at 24th Annual Needham Virtual Healthcare Conference
Medium
Report
I-Mab to Present at 24th Annual Needham Virtual Healthcare Conference
Date
Time
Symbol
Headline
Impact
2/5
08:10 pm
imab
Form SCHEDULE 13D I-Mab Filed by: CBC Investment I-Mab Ltd
Low
Report
Form SCHEDULE 13D I-Mab Filed by: CBC Investment I-Mab Ltd
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
2/25
I-Mab Announces Upcoming Participation at March Conferences
15.1%
4/29 Form 20-F I-Mab For: Dec 31 14.5%
3/27 Form 6-K I-Mab For: Mar 27 8.2%
4/2 I-Mab Announces First Patient Dosed in Phase 1/2a Clinical Trial of Anti-CD47 Antibody, TJC4, in China 7.5%
3/13 I-Mab Biopharma Announces Development of TJM2 to Treat Cytokine Release Syndrome Associated with Severe and Critically-Ill Patients with Coronavirus Disease (COVID-19) 7.2%
3/30 Form 6-K I-Mab For: Mar 30 4.0%
4/17 Form 6-K I-Mab For: Apr 17 3.9%
4/15 I-Mab (IMAB) Investor Presentation - Slideshow [Seeking Alpha] 3.3%
2/10 I-Mab Announces Partial Exercise of Over-Allotment Option in Initial Public Offering 1.6%
4/24 I-Mab Announces Upcoming Participation at May Conferences 0.9%
4/29 Form 20-F I-Mab For: Dec 31 14.5%
3/27 Form 6-K I-Mab For: Mar 27 8.2%
4/2 I-Mab Announces First Patient Dosed in Phase 1/2a Clinical Trial of Anti-CD47 Antibody, TJC4, in China 7.5%
3/13 I-Mab Biopharma Announces Development of TJM2 to Treat Cytokine Release Syndrome Associated with Severe and Critically-Ill Patients with Coronavirus Disease (COVID-19) 7.2%
3/30 Form 6-K I-Mab For: Mar 30 4.0%
4/17 Form 6-K I-Mab For: Apr 17 3.9%
4/15 I-Mab (IMAB) Investor Presentation - Slideshow [Seeking Alpha] 3.3%
2/10 I-Mab Announces Partial Exercise of Over-Allotment Option in Initial Public Offering 1.6%
4/24 I-Mab Announces Upcoming Participation at May Conferences 0.9%
TOP News Decliners
3/13
Form 6-K I-Mab For: Mar 13
-15.9%
1/17 I-MAB Announces Pricing of U.S. Initial Public Offering -15.3%
3/30 I-Mab Submits IND Application to Initiate Study of TJM2 for Treatment of Cytokine Storm Associated with Severe COVID-19 in South Korea -7.4%
4/6 Form 6-K I-Mab For: Apr 06 -5.7%
4/6 I-Mab Announces Upcoming Participation at April Conferences -4.9%
3/11 I-Mab to Report Financial Results for Full Year 2019 and Provide Corporate Update on March 31, 2020 -3.9%
2/14 Form SEC STAFF LETTER I-Mab -3.0%
2/12 Phoenix Tree Holdings Limited (NASDAQ: IMAB) is now covered by analysts at China Renaissance Securities Ltd.. They set a "buy" rating on the stock. -1.6%
3/23 Form 6-K I-Mab For: Mar 23 -1.3%
4/28 Form 6-K I-Mab For: Apr 28 -0.6%
1/17 I-MAB Announces Pricing of U.S. Initial Public Offering -15.3%
3/30 I-Mab Submits IND Application to Initiate Study of TJM2 for Treatment of Cytokine Storm Associated with Severe COVID-19 in South Korea -7.4%
4/6 Form 6-K I-Mab For: Apr 06 -5.7%
4/6 I-Mab Announces Upcoming Participation at April Conferences -4.9%
3/11 I-Mab to Report Financial Results for Full Year 2019 and Provide Corporate Update on March 31, 2020 -3.9%
2/14 Form SEC STAFF LETTER I-Mab -3.0%
2/12 Phoenix Tree Holdings Limited (NASDAQ: IMAB) is now covered by analysts at China Renaissance Securities Ltd.. They set a "buy" rating on the stock. -1.6%
3/23 Form 6-K I-Mab For: Mar 23 -1.3%
4/28 Form 6-K I-Mab For: Apr 28 -0.6%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: